REG - Hikma Pharmaceutical - Holding(s) in Company <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

29/02/2016 14:00

RNS Number : 4959Q
Hikma Pharmaceuticals Plc
29 February 2016
For filings with the FCA include the annex

For filings with issuer exclude the annex


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
Hikma Pharmaceuticals PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):


3. Full name of person(s) subject to the
notification obligation:iii
Boehringer Ingelheim Corporation;
Boehringer Ingelheim USA Corporation;
Boehringer Ingelheim Auslandsbeteiligungs GmbH;
Boehringer Ingelheim International GmbH;
Boehringer Ingelheim Verwaltungs GmbH;
Dr. Karl Thomae GmbH;
C.H. Boehringer Sohn AG & Co. KG
4. Full name of shareholder(s)
(if different from 3.):iv
Boehringer Ingelheim Corporation
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
29 February 2016
6. Date on which issuer notified:
29 February 2016
7. Threshold(s) that is/are crossed or
reached: vi, vii
16%
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Indirect
Direct xi
Indirect xii
Direct
Indirect
GB00B0LCW083
0
0
40,000,000
40,000,000
0
16.67%
0


B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx




Nominal
Delta


Total (A+B+C)
Number of voting rights
Percentage of voting rights
40,000,000
16.67%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
Boehringer Ingelheim Corporation has the following parent undertakings:
Boehringer Ingelheim USA Corporation, a Delaware corporation (wholly owns the voting shares in Boehringer Ingelheim Corporation). 
Boehringer Ingelheim Auslandsbeteiligungs GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim USA Corporation).
 
Boehringer Ingelheim International GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim Auslandsbeteiligungs GmbH).
Boehringer Ingelheim Verwaltungs GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim International GmbH).
Dr. Karl Thomae GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim Verwaltungs GmbH).
C.H. Boehringer Sohn AG & Co. KG, a German limited partnership (wholly owns Dr. Karl Thomae GmbH). 
Proxy Voting:
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will acquire:

12. Date on which proxy holder will acquirevoting rights:



13. Additional information:
None
14. Contact name:
Stephan Bach (Corporate Treasury)
Eric Humbert (Corporate Treasury)
15. Contact telephone number:
Stephan Bach: +49 (6132) 77-3032
Eric Humbert: +49 (6132) 77-90717

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUKVORNWAUUAR